



*JFW*

PATENT  
ATTORNEY DOCKET NO. 06132/065003

Certificate of Mailing: Date of Deposit: July 26, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alma Woodberry  
Printed name of person mailing correspondence

*Alma Woodberry*  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Thomas P. Monath et al.	Art Unit:	1648
Serial No.:	10/789,842	Examiner:	Not Yet Assigned
Filed:	February 27, 2004	Customer No.:	21559
Title:	Flavivirus Vaccines		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of U.S. serial number 10/345,036, which was filed on January 15, 2003. Applicants note that references marked with an asterisk were listed to and/or cited by the Office in the prior applications and, therefore, copies of these references are not provided for this application.

Submission of this statement is not a representation that a search has been made,  
nor is the inclusion of information in this statement an admission that the information is  
material to patentability.

This statement is being filed before the receipt of a first Office action on the  
merits.

If there are any charges or any credits, please apply them to Deposit Account No.  
03-2095.

Respectfully submitted,

Date: July 26, 2004

Susan M. Michaud  
Susan M. Michaud, Ph.D.  
Reg. No. 42,885

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))		Attorney Docket No. 06132/065003  Serial No. 10/789,842  Applicant Thomas P. Monath et al.  Filing Date February 27, 2004  Group 1648  IDS Filed July 26, 2004				
U.S. PATENTS						
Examiner's Initials	Patent Number or Patent Publication Number	Issue Date or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
*	6,171,854 B1	01/09/01	Galler et al.			
	6,184,024 B1	02/06/01	Lai et al.			
*	6,696,281	02/24/04	Chambers et al.			
	03/0194801	10/16/03	Bonaldo et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 93/06214	04/01/93	WIPO			
*	WO 98/37911	09/03/98	WIPO			
*	WO 01/39802	07/06/01	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Arroyo et al., "Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Development," Trends in Molecular Medicine 7:350-354, 2001.					
*	Arroyo et al., "Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE)," Journal of Virology 75:934-942, 2001.					
	Bray et al., "Construction of Intertypic Chimeric Dengue Viruses by Substitution of Structural Protein Genes," Proc. Natl. Acad. U.S.A. 88:10342-10346, 1991.					
*	Bray et al., "Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence," Journal of Virology 72:1647-1651, 1998.					
	Caufour et al., "Construction, Characterization and Immunogenicity of Recombinant Yellow Fever 17D-Dengue Type 2 Viruses," Virus Research 1-14, 2001.					
	Chambers et al., "Mutagenesis of the Yellow Fever Virus NS2B/3 Cleavage Site: Determinants of Cleavage Site Specificity and Effects on Polyprotein Processing and Viral Replication," J. Virol. 1600-1605, 1995.					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06132/065003
		Serial No.	10/789,842
		Applicant	Thomas P. Monath et al.
		Filing Date	February 27, 2004
		Group	1648
		IDS Filed	July 26, 2004
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))			

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Chambers et al., "Vaccine Development Against Dengue and Japanese Encephalitis: Report of a World Health Organization Meeting," Vaccine 15:1494-1502, 1997.
*	Chambers et al., "Yellow Fever/Japanese Encephalitis Chimeric Viruses: Construction and Biological Properties," Journal of Virology 73:3095-3101, 1999.
	Coia et al., "Nucleotide and Complete Amino Acid Sequences of Kunjin Virus: Definitive Gene Order and Characteristics of the Virus-Specified Proteins," J. Gen. Virol. 69:1-21, 1988.
*	dos Santos et al., "Determinants in the Envelope E Protein and Viral RNA Helicase NS3 that Influence the Induction of Apoptosis in Response to Infection with Dengue Type 1 Virus," Virology 274:292-308, 2000.
	Duarte dos Santos et al., "Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213," Virus Research 35:35-41, 1995.
	Galler et al., "The Yellow Fever 17D Vaccine Virus: Molecular Basis of Viral Attenuation and its Use as an Expression Vector," Braz. J. Biol. Res. 30:157-168, 1997.
	Galler et al., "Genetic Variability Among Yellow Fever Virus 17D Substrains," Vaccine 16:1-5, 1998.
*	Guirakhoo et al., "Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine," Journal of Virology 75:7290-7304, 2001.
*	Hurrelbrink and McMinn, "Attenuation of Murray Valley Encephalitis Virus by Site-Directed Mutagenesis of the Hinge and Putative Receptor-Binding Regions of the Envelope Protein," Journal of Virology 75:7692-7702, 2001.
*	Kanesa-athan et al., "Safety and Immunogenicity of Attenuated Dengue Virus Vaccines (Aventis Pasteur) in Human Volunteers," Vaccine 19:3179-3188, 2001.
	Lai et al., "Evaluation of Molecular Strategies to Develop a Live Dengue Vaccine," Clin. Diag. Virol. 10:173-179, 1998.
	Mandl et al., "Sequence of the Genes Encoding the Structural Proteins of the Low-Virulence Tick-Borne Flaviviruses Langat TP21 and Yelantsev," Virol. 185:891-895, 1991.
	Mandl et al., "Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic-Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses," Virol. 194:173-184, 1993.
	Marchevsky et al., "Phenotypic Analysis of Yellow Fever Virus Derived from Complementary DNA," American J. Tropical Medicine & Hygiene 52:75-80, 1995.
*	McMinn, "The Molecular Basis of Virulence of the Encephalitogenic Flaviviruses," Journal of General Virology 78:2711-2722, 1997.
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	06132/065003
	Serial No.	10/789,842
	Applicant	Thomas P. Monath et al.
	Filing Date	February 27, 2004
	Group	1648
	IDS Filed	July 26, 2004

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

*	Monath et al., "Single Mutation in the Flavivirus Envelope Protein Hinge Region Increases Neurovirulence for Mice and Monkeys but Decreases Viscerotropism for Monkeys: Relevance to Development and Safety Testing of Live, Attenuated Vaccines," Journal of Virology 76:1932-1943, 2002.
*	Monath, "Molecular Distinctions Between Attenuated (Vaccine) and Virulent Yellow Fever Viruses," In, Plotkin SA and Orenstein WA (eds). Vaccines, 3 <sup>rd</sup> edition, Saunders (Philadelphia), pp. 815-879, 1999.
	Pletnev et al., "Construction and Characterization of Chimeric Tick-Borne Encephalitis/Dengue Type 4 Viruses," Proc. Natl. Acad. Sci. U.S.A. 89:10532-10536, 1992.
*	Rey et al., "The Envelope Glycoprotein From Tick-Borne Encephalitis Virus at 2Å Resolution," Nature 375:291-298, 1995.
	Rice et al., "Transcription of Infectious Yellow Fever RNA from Full-Length cDNA Templates Produced by In Vitro Ligation," The New Biologist 1:285-296, 1989.
	Shiu et al., "Genomic Sequence of the Structural Proteins of Louping III Virus: Comparative Analysis with Tick-Borne Encephalitis Virus," Virology 180:411-415, 1991.
	Stocks et al., "Signal Peptidase Cleavage at the Flavivirus C-prM Junction: Dependence on the Viral NS2B-3 Protease for Efficient Processing Requires Determinants in C, the Signal Peptide, and prM," J. Virol. 72:2141-2149, 1998.
	Venugopal et al., "Towards a New Generation of Flavivirus Vaccines," Vaccines 12:966-975, 1994.
*	Wang et al., "Comparison of the Genomes of the Wild-Type French Viscerotropic Strain of Yellow Fever Virus with its Vaccine Derivative French Neurotropic Vaccine," Journal of General Virology 76:2749-2755, 1995.
*	Chambers et al., U.S. Patent Application Serial No. 09/121,587, filed July 23, 1998.
	Chambers et al., U.S. Patent Application Serial No. 10/701,122, filed November 4, 2003.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.